Antibody discovery research paves the way for new therapeutics. The search for the right antibody for a specific therapeutic application necessitates several iterations of antibody production and ...

A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

AlphaFold 3 also has the ability to predict antibody-protein binding ... to deal with,” Lowe says. “The drug discovery and development process is so long, with so many twists and turns ...

Integral Molecular, a leader in antibody discovery technologies, is proud to announce that the FDA has accepted their ...

In this article, we present a framework designed to evaluate the progress and impact of AI tools across various use cases in drug discovery ... of the development process. Predictive solutions ...

It can take 10–15 years and – accounting for development failures – cost over $500 million ... target-agnostic approaches to drug discovery. The bottleneck has shifted – to one of prioritization. “The ...

In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibody discovery and development.

meticulously designed for antibody and autoantibody profiling in biomarker discovery. This powerful platform delivers key insights into immune responses to disease and identifies targetable biomarkers ...

The significant growth potential in the evolving AI healthcare industry is driving investor interest in the sector as drug discovery and development companies continue to announce new-gen ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based ...